SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Resectable NSCLCSeptember 30, 2026

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

A pathology analysis of patients enrolled in the Japanese JCOG0802/WJOG4607L trial, published in the Journal of Thoracic Oncology, found that STAS independently predicted shorter relapse-free survival in stage IA (pT1a/bN0) non-small cell lung cancer (NSCLC) whether the tumour had been removed by lobectomy or by segmentectomy, although it independently predicted overall survival only after lobectomy.
Share

In brief

  • Of 593 tumours from the JCOG0802/WJOG4607L trial of segmentectomy versus lobectomy, 227 (38.3%) showed spread through air spaces (STAS) on review by 32 expert pulmonary pathologists.
  • STAS was associated with shorter relapse-free survival (HR 2.204) and overall survival (HR 1.917), both p<0.001, and remained an independent adverse factor on multivariable analysis.
  • Local recurrence was more frequent in tumours with STAS after lobectomy (p=0.012) and after segmentectomy (p=0.002).
  • STAS independently predicted shorter relapse-free survival in both surgical subgroups, and shorter overall survival only in the lobectomy subgroup.
  • In invasive non-mucinous adenocarcinoma, grade 3 histology was strongly associated with STAS, and grade 3 was the only one of the two factors to predict overall survival independently.

Study at a glance

  • Cohort: 593 tumours from patients in the JCOG0802/WJOG4607L randomised trial
  • Population: stage IA NSCLC, pT1a/bN0
  • Procedures: lobectomy (n=294) and segmentectomy (n=299)
  • Pathology review: STAS and histologic grade assessed by 32 expert pulmonary pathologists from several countries
  • Endpoints: relapse-free survival (RFS) and overall survival (OS)
  • STAS present: 227 of 593 tumours (38.3%)
  • Main result: RFS HR 2.204 and OS HR 1.917 with STAS, both p<0.001
  • Not reported: absolute recurrence and survival rates by STAS status, and confidence intervals for the hazard ratios (in the abstract)

A segmentectomy trial that left the place of STAS open

JCOG0802/WJOG4607L randomised patients with small peripheral NSCLC to segmentectomy or lobectomy. STAS and histologic tumour grade had both been reported as adverse prognostic factors in NSCLC before this analysis.

What had not been settled, according to the authors, was how either factor bears on the extent of resection. The trial population gave them a way to test that question in patients who had been randomised between the two operations and followed under a common protocol.

STAS in 38% of tumours, with roughly twice the hazard of relapse

Across all 593 tumours, the presence of STAS gave a hazard ratio of 2.204 for relapse-free survival and 1.917 for overall survival, each with p<0.001.

On multivariable analysis STAS remained an independent adverse factor for relapse-free survival (p<0.001) and for overall survival (p=0.009). STAS was scored by 32 expert pulmonary pathologists from around the world, a feature that can be difficult to score consistently.

Higher local recurrence with STAS after either operation

The association between STAS and local recurrence reached p=0.012 in the 294 tumours removed by lobectomy and p=0.002 in the 299 removed by segmentectomy.

STAS also predicted shorter relapse-free survival independently within each surgical subgroup. For overall survival the picture differed by procedure: STAS was an independent predictor in the lobectomy subgroup and did not reach that threshold in the segmentectomy subgroup. The subgroups are each about half the size of the full cohort, and the abstract does not offer an explanation for the difference.

Grade 3 adenocarcinoma travelled with STAS and predicted survival on its own

Among invasive non-mucinous adenocarcinomas, grade 3 histology showed a strong association with STAS (p<0.001), and grade 3 tumours had poor outcomes.

Both STAS and grade 3 independently predicted shorter relapse-free survival, whereas only grade 3 independently predicted overall survival. The two features are closely associated, and within adenocarcinomas the overall survival signal appeared to track with grade more than with STAS.

Both factors proposed for risk stratification in pT1a/bN0 disease

The authors conclude that the results reinforce STAS and high-grade adenocarcinoma as clinically significant prognostic factors, and that they support incorporating both into risk stratification for patients with pT1a/bN0 NSCLC.

In this analysis STAS was scored by pathologists on tumours that had already been resected. For STAS to guide the choice between segmentectomy and lobectomy, it would need to be identified before or during the operation, and the abstract does not address how reliably that can be done.

Sources

  1. Journal of Thoracic Oncology. Prognostic Significance of Spread Through Airspaces (STAS) in Stage Ia/bN0 Non-small Cell Lung Cancer – An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Sabina Berezowska, Lukas Bubendorf and Paul Hofman.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa
Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Nov 13 2026
ILCS 2026
Biomarkers

ctDNA-guided decisions in lung cancer: ready or not?

M. Das
Nov 13 2026
ILCS 2026

Welcome & introduction

S. PetersA. Addeo
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Sep 19 2026
RESEARCH
Resectable NSCLC

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

S. Saw
Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 31 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi